| Literature DB >> 19685146 |
Remilio A L Schoop1, Mathieu H M Noteborn, Robert J Baatenburg de Jong.
Abstract
Despite recent advances, the prognosis of oral squamous cell carcinoma is still poor. Therapeutic options such as radiotherapy, chemotherapy, surgery and the novel treatment option gene therapy are being investigated in animal models. Diverse models have been studied to induce oral squamous cell carcinomas. The carcinogenic 4-nitroquinoline-1-oxide (4NQO) model has proven to be successful although until now it is unknown at what time point the established tumor is a representative squamous cell carcinoma and has a suitable volume for scientific treatment. For this end we applied 4NQO 3 times a week during 16 weeks and measured the volume of tumor tissue each week until the end of the experiment at 40 weeks. Concurrent histopathology at different time points up to the end of the experiment revealed that all mice bearing oral tumors were diagnosed with squamous cell carcinoma. Immunohistochemistry with markers cyclin D1 and E-cadherin revealed that the generated mouse oral tumors showed strong similarities with the described immunopathology in human oral tumors. The 4NQO model is a suitable alternative for preclinical gene therapy experiments with primary oral tumors. Future survey of therapeutic options in the carcinogenic 4NQO model should be conducted around 40 weeks after the start of the treatment.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19685146 PMCID: PMC2770130 DOI: 10.1007/s10735-009-9228-z
Source DB: PubMed Journal: J Mol Histol ISSN: 1567-2379 Impact factor: 2.611
Fig. 1Chemical structure of 4-nitroquinoline 1-oxide (4NQO)
Fig. 2Histological findings of tongue in mice treated with 4NQO during 16 weeks. a Normal tongue with no histopathological changes 24 weeks after starting the experiment. b Mild dysplasia after 24 weeks. c Moderate dysplasia after 28 weeks. d Severe dysplasia after 28 weeks. e Invasive squamous cell carcinoma after 32 weeks. Original magnification ×10
Fig. 3Histopathology and immunohistochemistry staining with biomarkers cyclin D1 and E-cadherin. The left panel shows mild dysplasia after 24 weeks, the right panel shows squamous cell carcinoma after 40 weeks. Hematoxylin-eosin staining (HE) of mild dysplasia (a) and of squamous cell carcinoma (b) are shown. Cyclin D1 is primarily expressed in basal cells in mild dysplasia (c) and throughout the tumor and in tumor nests in squamous cell carcinoma (d). E-cadherin is expressed in the parabasal cell layer of the epithelium, but not on the surface of basal cells in mild dysplasia (e) and is partly lost in the invasive front of squamous cell carcinoma (f). Original magnification ×4
Fig. 4Volume of established tumors. Tumors were measured in three dimensions and the volume was calibrated in mm3. The volumes and ranges of each time point after the start of the treatment are shown